Frank Sciurba News Today

The group set up camp saturday after a march in a nearby town in support of two ranchers. Dwight hammond and his son steven were convicted of setting fires on federal land in 2001. And in 2006 served jail time. They say it wasnt arson, but controlled burns to protect their property. In october a judge added four more years to their sentence. Ammon bundy is leading the occupation. He says theyre fighting back against the governments expansion of the over 100 yearold federal wildlife refuge at the...

Equations that dont use racially and ethnically adjusted spirometry results to help determine eligibility for chronic obstructive pulmonary disease (COPD) clinical trials may lead to higher percentages of Black patients enrolled, according to research published at the ATS 2024 International Conference.

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and...

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON...

/PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field (PEF) therapies for COPD, soft tissue, and cardiac arrhythmias, has...

Many people have a lingering cough after a COVID infection. Experts explain why a post-COVID cough can last so long and what you can do to feel better.

Amoeba Biology Reveals Potential Treatment Target for Lung Disease Illustration of cilia and surface hydration among normal airway cells and those affected by cigarette smoke. Newswise — In a series of experiments that began with amoebas — single-celled organisms that extend podlike appendages to move around — Johns Hopkins Medicine scientists say they have identified a genetic pathway that could be activated to help sweep out mucus from the lungs of people with chronic obstructive pulmo...

Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis News provided by Share this article Share this article SAN CARLOS, Calif., Feb. 22, 2021 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announces U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to commence its pivotal clinical trial called RheSolve, which is design...